Table 3.
Association of a CAD GRS and Its Components with the Primary Endpoint of JUPITER and Interactions with Randomized Statin Allocation
|
Stratified by Statin Allocation |
Stratified by Statin Allocation, Baseline LipidaAdjusted |
||||||
|---|---|---|---|---|---|---|---|
| GRS | Overallb | Placebo | Statin | p int. | Placebo | Statin | p int. |
| CAD.grs | 1.12 (0.98–1.27), 0.096 | 1.22 (1.03–1.44), 0.018 | 0.95 (0.77–1.18), 0.65 | 0.064 | 1.21 (1.02–1.42), 0.026 | 0.96 (0.78–1.18), 0.69 | 0.079 |
| CAD.resids.grs | 0.92 (0.80–1.05), 0.20 | 1.19 (1.01–1.40), 0.04 | 0.98 (0.80–1.21), 0.89 | 0.149 | 1.18 (1.00–1.38), 0.054 | 0.99 (0.80–1.22), 0.90 | 0.172 |
| comp.1 | 1.07 (0.94–1.22), 0.30 | 1.21 (1.02–1.44), 0.028 | 0.87 (0.72–1.07), 0.19 | 0.018 | 1.20 (1.00–1.43), 0.047 | 0.87 (0.71–1.07), 0.20 | 0.019 |
| comp.2 | 1.19 (1.04–1.36), 0.01 | 1.32 (1.12–1.57), 0.0013 | 1.00 (0.81–1.23), 0.98 | 0.042 | 1.29 (1.09–1.54), 0.0038 | 0.95 (0.77–1.18), 0.66 | 0.042 |
| comp.3 | 1.12 (0.99–1.28), 0.075 | 1.21 (1.02–1.42), 0.026 | 1.00 (0.81–1.23), 0.99 | 0.166 | 1.21 (1.03–1.43), 0.022 | 1.00 (0.81–1.24), 0.99 | 0.167 |
| comp.4 | 1.03 (0.91–1.18), 0.60 | 1.01 (0.86–1.18), 0.94 | 1.09 (0.88–1.34), 0.45 | 0.631 | 1.00 (0.84–1.17), 0.96 | 1.11 (0.90–1.38), 0.33 | 0.571 |
| comp.5 | 1.04 (0.91–1.19), 0.54 | 1.06 (0.90–1.25), 0.51 | 1.01 (0.82–1.24), 0.95 | 0.666 | 1.06 (0.90–1.25), 0.50 | 0.99 (0.80–1.23), 0.96 | 0.614 |
| comp.6 | 1.04 (0.91–1.18), 0.57 | 1.00 (0.85–1.18), 0.99 | 1.10 (0.90–1.36), 0.35 | 0.456 | 1.00 (0.85–1.18), 0.98 | 1.12 (0.90–1.38), 0.31 | 0.427 |
| comp.7 | 1.03 (0.90–1.17), 0.71 | 0.99 (0.84–1.17), 0.91 | 1.10 (0.89–1.36), 0.38 | 0.48 | 0.99 (0.84–1.17), 0.92 | 1.10 (0.89–1.36), 0.40 | 0.451 |
| comp.8 | 1.10 (0.97–1.25), 0.15 | 1.11 (0.94–1.31), 0.22 | 1.10 (0.89–1.37), 0.38 | 0.831 | 1.12 (0.95–1.31), 0.19 | 1.11 (0.90–1.38), 0.34 | 0.824 |
| comp.9 | 1.14 (1.00–1.30), 0.047 | 1.07 (0.91–1.26), 0.41 | 1.26 (1.02–1.57), 0.033 | 0.202 | 1.07 (0.91–1.26), 0.40 | 1.27 (1.02–1.57), 0.031 | 0.195 |
Hazard ratios, 95% confidence intervals, and p values from Cox-proportional hazards models minimally adjusted for age, sex, and 10 principal components of sub-European population structure or additional adjustment for baseline lipids as indicated. P int. refers to the p value for the interaction between each specified component and randomized rosuvastatin allocation. Components derived from SVD of phenotype beta coefficients using pt = 0.05 (Subjects and Methods).
a
Baseline LDL-C, HDL-C, triglycerides.
b
Additional adjustment for randomized statin allocation.